Concepedia
Publication | Open Access
Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant <i>Escherichia coli</i> Bacteremic Urinary Tract Infections
82
Citations
14
References
2022
Year
ClinicalTrials.gov Identifier: NCT02142751.
A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation
Mary E. Charlson, Peter Pompei, Kathy L. Aleš, +1
Journal of Chronic Diseases
Prognostic AssessmentLongitudinal StudiesPrognostic ComorbidityRetrospective Cohort StudyPsychiatry +9
1987
48.8K
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance
Anna-Pelagia Magiorakos, Arjun Srinivasan, Roberta B. Carey, +14
Clinical Microbiology and Infection
Antimicrobial Resistance GeneAntimicrobial SusceptibilityHealth SciencesMedicinePandrug-resistant Bacteria +9
2011
13.3K
Global increase and geographic convergence in antibiotic consumption between 2000 and 2015
Eili Klein, Thomas P. Van Boeckel, Elena Martínez, +5
Proceedings of the National Academy of Sciences
2018
3.1K
Health Care–Associated Bloodstream Infections in Adults: A Reason To Change the Accepted Definition of Community-Acquired Infections
N. Deborah Friedman
Annals of Internal Medicine
2002
1.6K
-Lactam/ -Lactam Inhibitor Combinations for the Treatment of Bacteremia Due to Extended-Spectrum -Lactamase-Producing Escherichia coli: A Post Hoc Analysis of Prospective Cohorts
Jesús Rodríguez‐Baño, M.D. Navarro, Pilar Retamar, +2
Clinical Infectious Diseases
356
Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial
Keith S. Kaye, Louis B. Rice, Aaron Dane, +7
2019
135
Pharmacodynamics of Fosfomycin: Insights into Clinical Use for Antimicrobial Resistance
Fernando Docobo-Pérez, George L. Drusano, Adam Johnson, +10
Antimicrobial Agents and Chemotherapy
Fosfomycin ResistanceAntibiotic AdjuvantAntimicrobial ChemotherapyAntibiotic ResistanceClinical Use +16
2015
109
Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing <i>Escherichia coli</i> (FOREST): study protocol for an investigator-driven randomised controlled trial
Clara Rosso-Fernández, Jesús Sojo-Dorado, Ángel Díaz Barriga, +7
BMJ Open
65
Exploration of the Pharmacokinetic-Pharmacodynamic Relationships for Fosfomycin Efficacy Using an <i>In Vitro</i> Infection Model
Brian VanScoy, Jennifer McCauley, Evelyn J. Ellis‐Grosse, +4
Pharmacokinetic-pharmacodynamic RelationshipsFosfomycin EfficacyAntimicrobial ChemotherapyFosfomycin Agar MicPharmacodynamic Modeling +15
56
Role of inoculum and mutant frequency on fosfomycin MIC discrepancies by agar dilution and broth microdilution methods in Enterobacteriaceae
Mónica Ballestero-Téllez, Fernando Docobo-Pérez, José Manuel Rodríguez-Martínez, +5
Antimicrobial SusceptibilityAgar DilutionMutant FrequencyBacteriologyMicrodilution Methods +4
2017
42
Page 1